Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib

医学 舒尼替尼 肾细胞癌 临床终点 内科学 肾切除术 临床试验 肿瘤科 不利影响 无进展生存期 随机对照试验 泌尿科 外科 肾 化疗
作者
Axel Bex,Peter F.A. Mulders,Michael A.S. Jewett,John Wagstaff,Johannes V. van Thienen,Christian U. Blank,Roland van Velthoven,Maria del Pilar Laguna,Lori Wood,Harm H.E. van Melick,Maureen J.B. Aarts,Jean-Baptiste Lattouf,Thomas Powles,Igle J. de Jong,Sylvie Rottey,Bertrand Tombal,Sandrine Marréaud,Sandra Collette,Laurence Collette,John B.A.G. Haanen
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:5 (2): 164-164 被引量:498
标识
DOI:10.1001/jamaoncol.2018.5543
摘要

Importance: In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC) have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the optimal sequence of surgery and systemic therapy is unknown. Objective: To examine whether a period of sunitinib therapy before CN improves outcome compared with immediate CN followed by sunitinib. Design, Setting, and Participants: This randomized clinical trial began as a phase 3 trial on July 14, 2010, and continued until March 24, 2016, with a median follow-up of 3.3 years and a clinical cutoff date for this report of May 5, 2017. Patients with mRCC of clear cell subtype, resectable primary tumor, and 3 or fewer surgical risk factors were studied. Interventions: Immediate CN followed by sunitinib therapy vs treatment with 3 cycles of sunitinib followed by CN in the absence of progression followed by sunitinib therapy. Main Outcomes and Measures: Progression-free survival was the primary end point, which needed a sample size of 458 patients. Because of poor accrual, the independent data monitoring committee endorsed reporting the intention-to-treat 28-week progression-free rate (PFR) instead. Overall survival (OS), adverse events, and postoperative progression were secondary end points. Results: The study closed after 5.7 years with 99 patients (80 men and 19 women; mean [SD] age, 60 [8.5] years). The 28-week PFR was 42% in the immediate CN arm (n = 50) and 43% in the deferred CN arm (n = 49) (P = .61). The intention-to-treat OS hazard ratio of deferred vs immediate CN was 0.57 (95% CI, 0.34-0.95; P = .03), with a median OS of 32.4 months (95% CI, 14.5-65.3 months) in the deferred CN arm and 15.0 months (95% CI, 9.3-29.5 months) in the immediate CN arm. In the deferred CN arm, 48 of 49 patients (98%; 95% CI, 89%-100%) received sunitinib vs 40 of 50 (80%; 95% CI, 67%-89%) in the immediate arm. Systemic progression before planned CN in the deferred CN arm resulted in a per-protocol recommendation against nephrectomy in 14 patients (29%; 95% CI, 18%-43%). Conclusions and Relevance: Deferred CN did not improve the 28-week PFR. With the deferred approach, more patients received sunitinib and OS results were higher. Pretreatment with sunitinib may identify patients with inherent resistance to systemic therapy before planned CN. This evidence complements recent data from randomized clinical trials to inform treatment decisions in patients with primary clear cell mRCC requiring sunitinib. Trial Registration: ClinicalTrials.gov identifier: NCT01099423.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
隐形曼青的应助被科研通管家采纳,获得10
刚刚
开朗尔蓝发布了新的文献求助10
刚刚
JamesPei的应助被科研通管家采纳,获得10
刚刚
液氧发布了新的文献求助10
刚刚
刚刚
ding的应助被科研通管家采纳,获得10
刚刚
Ava的应助被科研通管家采纳,获得10
1秒前
CodeCraft的应助被科研通管家采纳,获得10
1秒前
深情安青的应助被科研通管家采纳,获得10
1秒前
爆米花的应助被科研通管家采纳,获得10
1秒前
aajhajkahna的应助被科研通管家采纳,获得10
1秒前
MichaelQiang的应助被科研通管家采纳,获得10
1秒前
ding的应助被科研通管家采纳,获得10
1秒前
桐桐的应助被科研通管家采纳,获得10
2秒前
在水一方的应助被科研通管家采纳,获得10
2秒前
桐桐的应助被科研通管家采纳,获得10
2秒前
重要语薇发布了新的文献求助10
2秒前
隐形曼青的应助被科研通管家采纳,获得10
2秒前
2秒前
上官若男的应助被ICE采纳,获得10
2秒前
SciGPT的应助被科研通管家采纳,获得10
2秒前
Ava的应助被ICE采纳,获得10
2秒前
Owen的应助被科研通管家采纳,获得10
2秒前
隐形曼青的应助被ICE采纳,获得10
2秒前
英俊的铭的应助被ICE采纳,获得10
2秒前
英姑的应助被ICE采纳,获得10
2秒前
2秒前
3秒前
Ava的应助被ICE采纳,获得10
3秒前
Jasper的应助被ICE采纳,获得10
3秒前
zhangyupei的应助被机智的方盒采纳,获得10
3秒前
3秒前
李爱国的应助被corleeang采纳,获得10
4秒前
ojoijn完成签到,获得积分10
4秒前
4秒前
Zhangyuanjie完成签到,获得积分10
4秒前
一一发布了新的文献求助10
4秒前
Lucas的应助被hhh采纳,获得10
5秒前
JLL丽丽发布了新的文献求助10
5秒前
在水一方的应助被betterlouse采纳,获得10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183046
求助须知:如何正确求助?哪些是违规求助? 9572370
关于积分的说明 21824411
捐赠科研通 7779694
什么是DOI,文献DOI怎么找? 3433792
关于科研通互助平台的介绍 2558024
邀请新用户注册赠送积分活动 2479971